Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment

Future Microbiology

Volumn 10, Issue 8, 2015, Pages 1257-1260

  Srikrishna, Geetha ^a,b   Gupta, Shashank ^a,b   Dooley, Kelly E ^a   Bishai, William R ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

adjunctive therapy; bedaquiline; cardiotoxicity; drug resistant tuberculosis; verapamil

Indexed keywords

BEDAQUILINE; VERAPAMIL; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

DRUG POTENTIATION; HEART ARRHYTHMIA; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QTC INTERVAL; REVIEW; TREATMENT OUTCOME; TUBERCULOSIS; ARRHYTHMIAS, CARDIAC; COMBINATION DRUG THERAPY;

ANTITUBERCULAR AGENTS; ARRHYTHMIAS, CARDIAC; DIARYLQUINOLINES; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS; VERAPAMIL;

EID: 84940670913     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/FMB.15.56     Document Type: Review

References (21)

1. Barry CE 3rd, Boshoff HI, Dartois V et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7(12), 845-855 (2009
2. Adams KN, Takaki K, Connolly LE et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145(1), 39-53 (2011
3. Adams KN, Szumowski JD, Ramakrishnan L. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-Tubercular drugs. J. Infect. Dis. 210(3), 456-466 (2014
4. Louw GE, Warren RM, Gey Van Pittius NC et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184(2), 269-276 (2011
5. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am. J. Respir. Crit. Care Med. 188(5), 600-607 (2013
6. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707), 223-227 (2005
7. Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline tmc207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52(8), 2831-2835 (2008
8. Diacon AH, Donald PR, Pym A et al. Randomized pilot trial of eight weeks of bedaquiline (tmc207) treatment for multidrug-resistant tuberculosis: long-Term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 56(6), 3271-3276 (2012
9. Diacon AH, Pym A, Grobusch MP et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med. 371(8), 723-732 (2014
10. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58(1), 574-576 (2014
11. Andries K, Villellas C, Coeck N et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS ONE 9(7), e102135 (2014
12. Gupta S, Tyagi S, Bishai WR. Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. Antimicrob. Agents Chemother. 59(1), 673-676 (2015
13. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline tmc207 for multidrugresistant tuberculosis. N. Engl. J. Med. 360(23), 2397-2405 (2009
14. Johnston A, Burgess CD, Hamer J. Systemic availability of oral verapamil and effect on PR interval in man. Br. J. Clin. Pharmacol. 12(3), 397-400 (1981
15. Fauchier L, Babuty D, Poret P, Autret ML, Cosnay P, Fauchier JP. Effect of verapamil on Qt interval dynamicity. Am. J. Cardiol. 83(5), 807-808, A810-801 (1999
16. Milberg P, Reinsch N, Osada N et al. Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of lqt3. Basic Res. Cardiol. 100(4), 365-371 (2005
17. Shimizu W, Ohe T, Kurita T et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J. Am. Coll. Cardiol. 26(5), 1299-1309 (1995
18. Aiba T, Shimizu W, Inagaki M et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J. Am. Coll. Cardiol. 45(2), 300-307 (2005
19. Oros A, Houtman MJ, Neco P et al. Robust anti-Arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced tdp arrhythmias is based upon a shared and a different mode of action. Br. J. Clin. Pharmacol. 161(1), 162-175 (2010
20. Liao WB, Bullard MJ, Kuo CT, Hsiao CT, Chu PH, Chiang CW. Anticholinergic overdose induced torsade de pointes successfully treated with verapamil. Jpn. Heart J. 37(6), 925-931 (1996
21. Annual Report of the National Institute for Research in Tuberculosis. http://www.nirt.res.in